Cargando…

Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin

BACKGROUND: We evaluated possible diagnostic and prognostic values of serum midkine in malignant pleural mesothelioma in comparison with those of serum mesothelin, a well-established diagnostic biomarker. METHODS: Serum mesothelin and midkine levels were determined with an enzyme-linked immunosorben...

Descripción completa

Detalles Bibliográficos
Autores principales: Ak, Guntulu, Tada, Yuji, Shimada, Hideaki, Metintas, Selma, Ito, Masaaki, Hiroshima, Kenzo, Tagawa, Masatoshi, Metintas, Muzaffer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362983/
https://www.ncbi.nlm.nih.gov/pubmed/28335760
http://dx.doi.org/10.1186/s12885-017-3209-5
_version_ 1782517083695742976
author Ak, Guntulu
Tada, Yuji
Shimada, Hideaki
Metintas, Selma
Ito, Masaaki
Hiroshima, Kenzo
Tagawa, Masatoshi
Metintas, Muzaffer
author_facet Ak, Guntulu
Tada, Yuji
Shimada, Hideaki
Metintas, Selma
Ito, Masaaki
Hiroshima, Kenzo
Tagawa, Masatoshi
Metintas, Muzaffer
author_sort Ak, Guntulu
collection PubMed
description BACKGROUND: We evaluated possible diagnostic and prognostic values of serum midkine in malignant pleural mesothelioma in comparison with those of serum mesothelin, a well-established diagnostic biomarker. METHODS: Serum mesothelin and midkine levels were determined with an enzyme-linked immunosorbent assay. We examined specimens from 95 Turkish cases with malignant pleural mesothelioma, 56 metastatic cancers to pleura, 27 other types of benign pleural diseases and 20 benign asbestos pleurisy. The cut-off values were 1.5 nmol/L for mesothelin and 421 pg/mL for midkine. RESULTS: Sensitivity and specificity of mesothelin were 51.6 and 71.4%, 51.6 and 85.2%, and 51.6 and 85% for differentiating mesothelioma from metastatic cancers to pleura, other benign pleural diseases and benign asbestos pleurisy, respectively. Sensitivity and specificity of midkine were 61.1 and 41.1%, 61.1 and 48.1%, and 61.1 and 75% to distinguish mesothelioma from metastatic cancers to pleura, other benign pleural diseases and benign asbestos pleurisy, respectively. Combination of both biomarkers did not improve the differential diagnostic efficacy. Mesothelin levels were elevated in the epitheloid type and in the advanced cases, but were not related to the prognosis. In contrast, elevated baseline levels of midkine were independently associated with a poor prognosis of mesothelioma patients after adjusting for the stage, the histological subtypes and treatment schedules (HR = 1.84; 95% CI: 1.09-3.09) (p = 0.022). CONCLUSIONS: Serum mesothelin showed moderate sensitivity and high specificity to differentiate malignant pleural mesothelioma from metastatic malignancy to pleura and from benign pleural diseases. In contrast, midkine was a useful marker for predicting prognosis of mesothelioma patients.
format Online
Article
Text
id pubmed-5362983
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-53629832017-03-24 Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin Ak, Guntulu Tada, Yuji Shimada, Hideaki Metintas, Selma Ito, Masaaki Hiroshima, Kenzo Tagawa, Masatoshi Metintas, Muzaffer BMC Cancer Research Article BACKGROUND: We evaluated possible diagnostic and prognostic values of serum midkine in malignant pleural mesothelioma in comparison with those of serum mesothelin, a well-established diagnostic biomarker. METHODS: Serum mesothelin and midkine levels were determined with an enzyme-linked immunosorbent assay. We examined specimens from 95 Turkish cases with malignant pleural mesothelioma, 56 metastatic cancers to pleura, 27 other types of benign pleural diseases and 20 benign asbestos pleurisy. The cut-off values were 1.5 nmol/L for mesothelin and 421 pg/mL for midkine. RESULTS: Sensitivity and specificity of mesothelin were 51.6 and 71.4%, 51.6 and 85.2%, and 51.6 and 85% for differentiating mesothelioma from metastatic cancers to pleura, other benign pleural diseases and benign asbestos pleurisy, respectively. Sensitivity and specificity of midkine were 61.1 and 41.1%, 61.1 and 48.1%, and 61.1 and 75% to distinguish mesothelioma from metastatic cancers to pleura, other benign pleural diseases and benign asbestos pleurisy, respectively. Combination of both biomarkers did not improve the differential diagnostic efficacy. Mesothelin levels were elevated in the epitheloid type and in the advanced cases, but were not related to the prognosis. In contrast, elevated baseline levels of midkine were independently associated with a poor prognosis of mesothelioma patients after adjusting for the stage, the histological subtypes and treatment schedules (HR = 1.84; 95% CI: 1.09-3.09) (p = 0.022). CONCLUSIONS: Serum mesothelin showed moderate sensitivity and high specificity to differentiate malignant pleural mesothelioma from metastatic malignancy to pleura and from benign pleural diseases. In contrast, midkine was a useful marker for predicting prognosis of mesothelioma patients. BioMed Central 2017-03-23 /pmc/articles/PMC5362983/ /pubmed/28335760 http://dx.doi.org/10.1186/s12885-017-3209-5 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Ak, Guntulu
Tada, Yuji
Shimada, Hideaki
Metintas, Selma
Ito, Masaaki
Hiroshima, Kenzo
Tagawa, Masatoshi
Metintas, Muzaffer
Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin
title Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin
title_full Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin
title_fullStr Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin
title_full_unstemmed Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin
title_short Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin
title_sort midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362983/
https://www.ncbi.nlm.nih.gov/pubmed/28335760
http://dx.doi.org/10.1186/s12885-017-3209-5
work_keys_str_mv AT akguntulu midkineisapotentialnovelmarkerformalignantmesotheliomawithdifferentprognosticanddiagnosticvaluesfrommesothelin
AT tadayuji midkineisapotentialnovelmarkerformalignantmesotheliomawithdifferentprognosticanddiagnosticvaluesfrommesothelin
AT shimadahideaki midkineisapotentialnovelmarkerformalignantmesotheliomawithdifferentprognosticanddiagnosticvaluesfrommesothelin
AT metintasselma midkineisapotentialnovelmarkerformalignantmesotheliomawithdifferentprognosticanddiagnosticvaluesfrommesothelin
AT itomasaaki midkineisapotentialnovelmarkerformalignantmesotheliomawithdifferentprognosticanddiagnosticvaluesfrommesothelin
AT hiroshimakenzo midkineisapotentialnovelmarkerformalignantmesotheliomawithdifferentprognosticanddiagnosticvaluesfrommesothelin
AT tagawamasatoshi midkineisapotentialnovelmarkerformalignantmesotheliomawithdifferentprognosticanddiagnosticvaluesfrommesothelin
AT metintasmuzaffer midkineisapotentialnovelmarkerformalignantmesotheliomawithdifferentprognosticanddiagnosticvaluesfrommesothelin